FDA grants priority review to Lynparza combo therapy for metastatic prostate cancer
AstraZeneca and Merck’s top-selling PARP inhibitor Lynparza is possibly on its way to winning regulatory approval for yet another indication.
The FDA has accepted the supplemental new drug application and granted a priority review to Lynparza combination therapy for patients with metastatic castration-resistant prostate cancer, the companies announced Tuesday.
In the US, prostate cancer is the second most common cancer in male patients, and nearly 10-20% of men with advanced prostate cancer are estimated to develop castration-resistant prostate cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.